Rosenberg Matthew Hamilton Has $222,000 Stake in Danaher Co. (NYSE:DHR)

Rosenberg Matthew Hamilton grew its stake in Danaher Co. (NYSE:DHR) by 5.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 969 shares of the conglomerate’s stock after buying an additional 54 shares during the quarter. Rosenberg Matthew Hamilton’s holdings in Danaher were worth $222,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in DHR. FMR LLC boosted its position in Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after buying an additional 563,546 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in shares of Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after buying an additional 428,897 shares during the period. Montrusco Bolton Investments Inc. grew its stake in Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after buying an additional 397,671 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec raised its holdings in Danaher by 82.4% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 653,375 shares of the conglomerate’s stock worth $181,651,000 after acquiring an additional 295,187 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 2.0 %

DHR opened at $239.83 on Tuesday. The firm has a market cap of $173.22 billion, a price-to-earnings ratio of 45.77, a PEG ratio of 4.32 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm’s 50-day simple moving average is $235.52 and its 200-day simple moving average is $253.65. Danaher Co. has a twelve month low of $222.53 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the firm earned $2.02 earnings per share. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. Equities research analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s payout ratio is 20.61%.

Wall Street Analyst Weigh In

DHR has been the subject of several research analyst reports. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. Royal Bank of Canada reduced their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. KeyCorp raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus upped their target price on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Finally, Citigroup dropped their price objective on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.